Edwards Lifesciences (NYSE:EW) reported first-quarter results that exceeded analyst expectations and raised its full-year outlook, sending shares 2% higher in pre-market trading today.
The company posted adjusted earnings per share of $0.78, surpassing the consensus estimate of $0.73 by $0.05. Revenue totaled $1.65 billion, exceeding the $1.6 billion estimate and rising 16.7% year-over-year, or 12.7% on a constant currency basis.
Edwards increased its fiscal 2026 constant currency sales growth guidance to a range of 9% to 11%, up from the prior range of 8% to 10%. It also raised its full-year adjusted EPS outlook to $2.95 to $3.05, from $2.90 to $3.05. The midpoint of $3.00 exceeded the analyst consensus estimate of $2.97.
For the second quarter of 2026, the company projected revenue between $1.66 billion and $1.74 billion, with a midpoint of $1.70 billion slightly above the $1.683 billion consensus. Adjusted EPS guidance for the quarter was set between $0.70 and $0.76, with the midpoint of $0.73 below the $0.75 analyst estimate.